Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A

Huaren Health released its 2026 interim report, with total operating revenue of 2.825 billion yuan and net profit attributable to the parent company of 136 million yuan. Net cash inflow from operating activities was 410 million yuan, down 22.95% from the same period last year. The company's asset-liability ratio was 60.25%, gross margin was 34.72%, ROE was 6.41%, and diluted earnings per share was 0.34 yuan. The number of shareholders was 29,100, and the top ten shareholders held 65.97% of the total share capital.

Huaren Health released its 2026 interim report. First-half net profit attributable to the parent was 136 million yuan, up 31.0% year on year. Operating revenue was 2.82 billion yuan, up 12.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 132 million yuan, up 31.0% year on year. Net operating cash flow was 410 million yuan, down 23.0% year on year. Earnings per share were 0.3398 yuan. In the second quarter, operating revenue was 1.40 billion yuan, up 13.5% year on year, and net profit attributable to the parent was 56.57 million yuan, up 33.0% year on year. As of the end of the second quarter, the company's total assets were 5.468 billion yuan, down 0.4% from the end of the previous year, and net assets attributable to the parent were 2.119 billion yuan, up 1.1% from the end of the previous year. The company said its main operating businesses did not experience major changes during the reporting period. Pharmaceutical retail, pharmaceutical marketing, and drug research and development and production continued to advance steadily, and overall operations maintained steady growth.

Huaren Health has released its 2026 plan for a private placement of A-shares to specific investors. The company intends to issue shares to no more than 35 specific investors, with the total number of shares not exceeding 50 million. The total funds raised will not exceed 709 million yuan. The proceeds will be used for a smart manufacturing and sorting center project, a pharmaceutical research and development project, an information technology construction project, and to supplement working capital.

The drug registration and marketing authorization application for ferrous succinate tablets from Anhui Zhengyao Pharmaceutical Technology Co., Ltd., a wholly owned subsidiary of Huaren Health, has been accepted by the National Medical Products Administration. This anti-anemia drug is used for the treatment and prevention of iron deficiency anemia. It is indicated for the treatment of iron deficiency anemia caused by chronic blood loss, insufficient iron intake, malabsorption, and other reasons in adults and children, and is also suitable for the prevention of iron deficiency anemia in adults, pregnant women, and children.